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Respiratory syncytial virus (RSV) is considered the 
most common pathogen causing severe lower respira-
tory tract infections among infants and young chil-
dren. We describe the seasonality and geographical 
spread of RSV infection in 15 countries of the European 
Union and European Economic Area. We performed a 
retrospective descriptive study of weekly laboratory-
confirmed RSV detections between weeks 40/2010 
and 20/2016, in patients investigated for influenza-
like illness, acute respiratory infection or following 
the clinician’s judgment. Six countries reported 4,230 
sentinel RSV laboratory diagnoses from primary care 
and 14 countries reported 156,188 non-sentinel labo-
ratory diagnoses from primary care or hospitals. The 
median length of the RSV season based on sentinel 
and non-sentinel surveillance was 16 (range: 9–24) 
and 18 (range: 8–24) weeks, respectively. The median 
peak weeks for sentinel and non-sentinel detections 
were week 4 (range: 48 to 11) and week 4.5 (range: 
49 to 17), respectively. RSV detections peaked later 
(r = 0.56; p = 0.0360) and seasons lasted longer with 
increasing latitude (r = 0.57; p = 0.0329). Our data dem-
onstrated regular seasonality with moderate correla-
tion between timing of the epidemic and increasing 
latitude of the country. This study supports the use of 
RSV diagnostics within influenza or other surveillance 
systems to monitor RSV seasonality and geographical 
spread.
Background
Respiratory syncytial virus (RSV) is considered the 
major pathogen causing severe lower respiratory tract 
infections among infants and young children [1]. RSV 
is the most common cause of hospitalisation for acute 
lower respiratory tract infection in children younger 
than 5 years and is estimated to cause between 66,000 
and 199,000 deaths worldwide every year [2]. Its 
significance in causing substantial morbidity and hos-
pitalisation in the first year of life has been affirmed in 
a recent study and a meta-analysis [3,4]. In England, 
average annual hospital admission rates are 35.1 per 
1,000 children younger than 1 year and 5.31 per 1,000 
children aged 1–4 years [5]. In addition to children, RSV 
causes a substantial disease burden in elderly people 
and patients with chronic obstructive pulmonary dis-
ease [6,7].
RSV causes seasonal epidemics worldwide [8], with 
one to two epidemics each year [9] following latitudi-
nal gradients in timing, duration, seasonal amplitude 
and between-year variability [8,9]. In some studies, 
the seasonal periodicity has been connected to cli-
matic factors [9-11], but a common factor that explains 
all observed periodicity has not been established. 
Meteorological conditions such as temperature and 
high relative humidity have been reported as important 
predictors of RSV epidemics [9,12]. In the United States 
(US) and Japan, annual national and regional variation 
of RSV season onset and end has been reported [13-
15]. In the Nordic countries, a major outbreak often 
alternates with a minor one, with the minor peak in the 
spring and a major one the following winter [16-19], a 
phenomenon reported also in Croatia [20], Denmark 
[21] and Germany [22]. RSV antigenic groups A and B 
alternate in two-year cycles in Finland, with dominance 
of the group A viruses in years 1981–82, 1985–86 and 
1989–90 and the group B viruses 1983–84 and 1987–
88 [17,19], and different genotypes dominate the circu-
lation in consecutive epidemics in Korea [23]. In Spain, 
no biennial rhythm has been detected but rather a sta-
ble annual epidemic with a peak between week 52 and 
week 1 and circulation 2–8 weeks earlier than influenza 
viruses [24]. Similarly, in the United Kingdom (UK), one 
stable epidemic per year is observed [5].
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Figure 1
Non-sentinel (n = 14 countries) and sentinel (n = 6 countries) RSV detections by country, season and week of detection, EU/
EEA, 2010–2016
A. Non-sentinel surveillance
B. Sentinel surveillance
0
500
1,000
1,500
2,000
2,500
3,000
2010-2011
40 44 48 52 4 8 12 16 20 24 28 32 36
Nu
m
be
r o
f R
SV
 d
et
ec
tio
ns All countries
0
50
100
150
200
250
4044 4852 4 8 12 16 20242832 36
Denmark
0
200
400
600
800
1,000
40 44 4852 4 8 12 16 2024 2832 36
France
0
10
20
30
40
50
40 44 48 52 4 8 12 16 20 24 28 32 36
Nu
m
be
r o
f R
SV
 d
et
ec
tio
ns Germany
0
5
10
15
20
25
40444852 4 8 12 16 20242832 36
Iceland
0
20
40
60
80
100
120
4044 4852 4 8 12 16 2024 2832 36
Ireland
0
10
20
30
40
50
40 44 48 52 4 8 12 16 20 24 28 32 36
Latvia
0
10
20
30
40
50
40 44 48 52 4 8 12 16 20 24 28 32 36
Nu
m
be
r o
f R
SV
 d
et
ec
tio
ns
Week
Malta
0
100
200
300
4044 4852 4 8 12 16 20242832 36
Week
Netherlands
0
10
20
30
40
50
4044 4852 4 8 12 16 2024 2832 36
Week
Poland
0
20
40
60
80
40 44 48 52 4 8 12 16 20 24 28 32 36
Week
Portugal
0
10
20
30
40
50
4044 4852 4 8 12 16 2024 2832 36
Estonia
0
1
2
3
4
5
6
7
8
9
10
40444852 4 8 12 16 2024283236
Estonia
0
10
20
30
40
50
60
70
80
40 44 48 52 4 8 12 16 20 24 28 32 36
All countries
0
10
20
30
40
50
40444852 4 8 12 16 2024283236
Germany
0
10
20
30
40
50
60
4044 4852 4 8 12 16 2024 2832 36
France
0
1
2
3
4
5
6
7
8
9
10
40 44 48 52 4 8 12 16 20 24 28 32 36
Nu
m
be
r o
f R
SV
 d
et
ec
tio
ns
Nu
m
be
r o
f R
SV
 d
et
ec
tio
ns
Week
Netherlands
0
5
10
15
40444852 4 8 12 16 2024283236
Week
Slovenia
0
10
20
30
40
50
40444852 4 8 12 16 2024283236
Week
United Kingdom
0
100
200
300
400
40 44 48 52 4 8 12 16 20 24 28 32 36
Nu
m
be
r o
f R
SV
 d
et
ec
tio
ns
Week
Spain
0
100
200
300
400
500
40 44 48 52 4 8 12 16 20 24 28 32 36
Week
Sweden
0
200
400
600
800
1,000
40 44 48 52 4 8 12 16 20 24 28 32 36
Week
United Kingdom
2011-2012
2012-2013
2013-2014
2014-2015
2015-2016
1.2% mean threshold
EU/EEA: European Union/European Economic Area; RSV: respiratory syncytial virus.
The top left panel shows the pooled data for all included EU/EEA countries. Other panels show country-specific data by season.
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Immunoprophylaxis to prevent RSV infection with a 
neutralising monoclonal antibody, palivizumab, has 
been developed for administration to target groups on 
a monthly basis during the RSV season [25]. However, 
this drug is limited to high-risk infants, the cost pro-
hibits its use in low- and middle-income countries and 
the data on effectiveness of the drug in children at 
high risk other than infants born at gestational age < 33 
weeks and in children with chronic lung and heart dis-
eases are limited [26]. The demonstrated high disease 
burden of RSV infection has created a longstanding 
interest in RSV vaccines. Approximately 60 RSV vac-
cine candidates are in preclinical to phase III clinical 
trials [27,28], with potential target groups including 
elderly people, pregnant women and infants. A vac-
cine is expected to enter the market within 5–10 years, 
presumably by 2025 [29]. As natural infection provides 
only limited protective immunity owing to evolution 
of the surface protein G and alternating dominance of 
antigenic groups A and B [30], most of the vaccine can-
didates target the fusion protein F, which is cross-reac-
tive across RSV subtypes [27]. To circumvent issues 
with alternating strains, it has been also suggested 
to consider inclusion of both RSV A and B in a future 
RSV vaccine [30]. To plan optimal future vaccination 
strategies, it is critically important to understand who 
is affected by RSV and to identify which groups are at 
risk of more severe RSV infection requiring hospitalisa-
tion or intensive care. RSV infection is not notifiable in 
the European Union (EU) and European Economic Area 
(EEA), except in Ireland, but many countries have a long 
tradition of reporting laboratory-confirmed RSV infec-
tions at national and international level. The European 
Influenza Surveillance Network (EISN) collects RSV 
data for the purpose of interpreting the reports of influ-
enza-like-illness (ILI); these data can also be used to 
analyse seasonality of RSV [31].
Inter-country comparative analysis of seasonal circu-
lation of RSV across Europe is lacking as most of the 
published literature focuses on individual countries. 
Our study describes the seasonality of RSV in 15 coun-
tries in the EU/EEA, specifically the start and peak of 
the season, length of the season and geographical 
Figure 2
Timing of RSV season as observed by non-sentinel (n = 14 countries) and sentinel (n = 6 countries) surveillance, EU/EEA, 
2010–2016
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EU/EEA: European Union/European Economic Area; RSV: respiratory syncytial virus.
Left panels: median start week of RSV season start; middle panels: RSV season peak; Right panels: median RSV season length. Upper panels: 
observed by non-sentinel surveillance (14 countries); lower panels: observed by sentinel surveillance (6 countries). The dots represent 
the median value of a given country and the ends of the bars the minimum and maximum values of the range observed. The shift between 
the years is indicated by a dashed vertical line. Countries are displayed in order of increasing latitude coordinates of their barycentre. ‘All’ 
shows median, minimum and maximum values of the pooled results from all countries per surveillance system.
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spread, as a baseline description of RSV circulation in 
Europe. We further aimed to test if the data reported 
through influenza surveillance systems in use in EU/
EEA countries are appropriate to analyse RSV season-
ality, including more countries and a more detailed 
analysis than previous studies.
Methods 
Study design
We retrospectively studied laboratory-confirmed 
RSV detections reported weekly through EISN to the 
European Surveillance System (TESSy) hosted at the 
European Centre for Disease Prevention and Control 
(ECDC) between week 40/2010 and week 20/2016.
Study population and data
We included reports of laboratory-confirmed RSV 
infection based on PCR, antigen detection, serum 
antibody detection or virus isolation. Clinicians used 
either case definitions for ILI or acute respiratory infec-
tion (ARI) as the indication for sampling, or their own 
judgment and diagnostic need rather than a specific 
case definition [32]. The specimens received from cli-
nicians were tested for RSV in local or national labo-
ratories, and positive results were collected through 
national surveillance systems. Weekly aggregated data 
were reported from each participating country through 
TESSy and covered sentinel surveillance in primary 
care and/or non-sentinel surveillance in primary- and/
or hospital-care facilities where sampling is done for 
diagnostic purposes. The EU/EEA countries’ national 
Figure 3
Correlation between the RSV seasonal timing and geographical location of the reporting country, non-sentinel data, EU/
EEA, 2010–2016 (n = 14 countries)
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For calculation purposes, the calendar weeks were transformed into running numbers starting with 1. Calendar week 40 thus became week 
number 1, calendar week 41 week 2 etc. Week 53 was removed from the dataset.
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Table
RSV case definitions used for sampling, geographical location and numbers of RSV detections, by country and surveillance 
system, 15 EU/EEA countries, 2010–2016
Country 
name
Case definition for 
sampling
Surveillance 
system 
(sentinel or 
non-sentinel)
Latitude 
of the 
barycentre 
(°North)
Longitude 
of the 
barycentre 
(°East)
Number 
of RSV 
seasons 
included
Total 
number of 
detections
Mean 
number of 
detections 
per 
season
Minimum 
number of 
detections 
per 
season
Maximum 
number of 
detections 
per 
season
Malta ILI Non-sentinel 35.9 14.5 5 840 168 34 264
Portugal ILI Non-sentinel 39.7 −9.2 4 1,305 326 79 626
Spain
Laboratory-confirmed 
RSV infection; testing 
based on clinical 
judgement
Non-sentinel 39.7 −3.3 6 12,706 2,118 1,278 2,965
Slovenia ARI, ILI Sentinel 46.2 14.9 4 191 48 41 59
France
ARI, ILI Non-sentinel 47.1 2.7 5 45,131 9,026 8,500 9,801
ARI, ILI Sentinel 47.1 2.7 5 1,611 322 243 382
Germany
ILI Non-sentinel 50.9 9.7 6 1,102 184 51 285
ARI, ILI Sentinel 50.9 9.7 6 1,046 174 56 336
Poland ILI Non-sentinel 51.7 19.3 6 1,748 291 132 464
The 
Netherlands
Laboratory-confirmed 
RSV infection; testing 
based on clinical 
judgement or ARIa
Non-sentinel 52.1 5.3 6 11,715 1,953 1,402 2,760
ILI Sentinel 52.1 5.3 5 200 40 32 50
United 
Kingdom
ARI, ILI Non-sentinel 52.7 −1.6 6 50,716 8,453 4,747 10,999
ARI, ILI Sentinel 52.7 −1.6 6 1,033 172 63 276
Ireland
Laboratory-confirmed 
RSV infection; testing 
based on clinical 
judgement; notifiable 
since 2012b
Non-sentinel 53.1 −7.4 6 4,443 741 547 945
Denmark
2010/11–2014/15: ARI, 
ILI;  
 
2015/16: testing based 
on clinical judgementc
Non-sentinel 55.9 10.9 6 3,006 501 45 2,568
Latvia
Laboratory-confirmed 
RSV infection; testing 
based on clinical 
judgement
Non-sentinel 56.8 24.4 6 2,187 365 239 442
Sweden
Laboratory-confirmed 
RSV infection; testing 
based on clinical 
judgement
Non-sentinel 58.9 15.4 6 18,736 3,123 1,419 5,118
Estonia
ARI, ILI Non-sentinel 59.0 25.5 6 1,849 308 177 373
ILI Sentinel 59.0 25.5 4 149 37 34 48
Iceland
Laboratory-confirmed 
RSV infection; testing 
based on clinical 
judgement
Non-sentinel 64.4 −21.1 6 704 117 32 193
Total
Sentinel
Non-sentinel 6 156,188 1,977 32 10,999
Sentinel 6 4,230 132 32 382
ARI: acute respiratory infection; EU/EEA: European Union/European Economic Area; GP: general practitioner; ILI: influenza-like illness; RSV: 
respiratory syncytial virus.
a ARI used in sentinel patients; however, RSV detections reported as non-sentinel detections [38,39].
b Irish case definition for notification of RSV since 2012 [40].
c In seasons 2010/11 to 2014/15, all diagnostic (ARI/ILI) and sentinel specimens (ILI). In season 2015/16, all RSV-positive laboratory results 
from the Danish National Microbiology Database including detections from hospitals and GPs.
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operational contact points for influenza surveillance 
were consulted regarding the use of case definitions 
and diagnostic detection methods. The reports were 
dated by date of specimen collection or date of labora-
tory diagnosis.
Data were included if a country reported for a minimum 
of four seasons and 5 weeks per season, with at least 
24 RSV detections per country, season and surveil-
lance system.
To explore geographical spread of RSV infections 
across the EU/EEA over time, latitude and longitude 
of the population centre (barycentre) of each country 
in decimal degrees were identified. Barycentres were 
calculated based on the 1 km population density grid 
provided by Eurostat, using the 2011 population data 
[33], except for Iceland for which the latest available 
population data were from 2006.
Data analysis
In line with similar previous work, RSV epidemic sea-
sons were defined as the weeks when RSV detec-
tions exceeded 1.2% of total RSV-positive specimens 
per country, surveillance system and season [8]. RSV 
detections also had to exceed the threshold continu-
ously during the season (one gap week was allowed). 
Sentinel and non-sentinel data were analysed sepa-
rately. Average threshold values over the seasons were 
calculated separately per country and surveillance 
system.
Based on the season-specific epidemic thresholds, we 
calculated the median weeks in which the RSV season 
started and peaked as well as the median length of the 
seasons. The start of the season was defined as the 
first week when the weekly RSV detections exceeded 
this threshold. The season peak was defined as the 
week in which the maximum number of RSV detec-
tions were reported. If two weeks had the same num-
ber of detections, the first week with this number was 
defined as the peak week.
The correlation between timing of the epidemic and 
distance of countries’ barycentre from the equator (lat-
itude) and Greenwich meridian (longitude) was stud-
ied by applying Pearson’s correlation to the median 
start and peak weeks as well as the length of each 
RSV epidemic; this was based on data from 14 of the 
15 participating countries providing non-sentinel data. 
Western longitudes were transformed to Eastern lon-
gitudes. Residues were tested for normal distribution 
by Shapiro–Wilk test. Any correlation (r) of 0–0.19 was 
regarded as very weak, 0.20–0.39 as weak, 0.40–0.59 
as moderate, 0.60–0.79 as strong and 0.80–1 as very 
strong [34]. The threshold of significance was set at 
p = 0.05. Fitted values of the correlation, the equation 
of the trend line and R2 values (goodness of fit of the 
regression line) were calculated. Data were analysed 
with Microsoft Excel 2013 and Stata 14.
Results 
Countries reporting RSV detections
Fifteen EU/EEA Member States reported 160,418 RSV 
detections during the study period: 156,188 through 
non-sentinel systems (14 reporting countries) and 4,230 
through sentinel surveillance systems (six reporting 
countries) (Table). At the non-sentinel sites, four coun-
tries used the ILI case definition only, four used the 
ILI and ARI case definitions and six used sampling for 
RSV based on clinical judgement without specific case 
definition (Table). At the sentinel sites, two countries 
used the ILI case definition only and four used both 
ILI and ARI case definitions. Eleven countries reported 
non-sentinel data for all six seasons (Table). The mean 
number of non-sentinel detections per season ranged 
from 117 in Iceland to 9,026 in France. The mean num-
ber of sentinel detections per season ranged from 37 in 
Estonia to 322 in France.
In Denmark, the surveillance system changed in 
2015/16 from an ILI/ARI-based system to register-
based retrieval of RSV-positive laboratory results from 
the Danish National Microbiology Database including 
detections from hospitals and general practitioners. 
Two countries, France and the UK, contributed 61% 
of the non-sentinel and 63% of the sentinel detec-
tions and therefore, their data influenced the overall 
European estimates the most.
Seasonality
Seasonality was observed by both types of surveillance 
(sentinel and non-sentinel) with the season threshold 
crossed in all countries in all years for both (Figure 1). 
All RSV seasons from 2010/11 to 2015/16 had a similar 
timing and epidemic course across Europe with some 
variation within and between countries (Figure 1). The 
highest numbers of detections were reported in sea-
sons 2012/13, 2013/14 and 2015/16. In peak weeks, 
more than 2,500 specimens per week were reported 
positive for RSV. The lowest figures were observed in 
2014/15 when France did not report RSV detections to 
TESSy because of a switch from one surveillance sys-
tem to another during that season. Each year, the RSV 
epidemic in Europe progressed rapidly after week 40 to 
its peak and decreased to baseline levels only around 
week 20, which was probably driven by the later timing 
of the RSV epidemics in the countries with more north-
erly location (see below). Although the sentinel data-
set was considerably smaller than the non-sentinel 
one, the sentinel detections followed similar patterns 
as non-sentinel detections and both showed a consid-
erable effect of the end of year holiday period (weeks 
52–1) (Figure 1  B) which is not as visible in the non-
sentinel data (Figure 1  A). For the sentinel data, the 
decrease in detections during the end-of-year holiday 
period was mainly shown in data from Germany (Figure 
1 B). While only eight detections of RSV in weeks 21–39 
were reported from sentinel sources over the study 
period, RSV was detected by non-sentinel surveillance 
throughout the year, albeit at low levels (18 detections 
7www.eurosurveillance.org
per week on average) during weeks 21–39. Compared 
with the remaining seasons, the season started 2–7 
weeks earlier in Denmark, Germany, Iceland, Ireland, 
Latvia, Malta, Poland and Sweden in 2012/13 and in 
Germany, Poland and Sweden in 2014/15 (Figure 1 A).
Based on analysis of the individual countries sepa-
rately or as a group, the median start of the RSV season 
was in week 49 in both surveillance systems (rang-
ing from week 41 to week 3 for the sentinel and from 
week 42 to week 8 for the non-sentinel data; Figure 2). 
The median peak week was in week 4 (range: 48 to 11) 
and 4.5 (range: 49 to 17), respectively, for sentinel and 
non-sentinel detections, roughly six weeks after the 
epidemic started. The median length of the RSV sea-
sons based on sentinel and non-sentinel surveillance 
was 16 (range: 9 to 24) and 18 weeks (range: 8 to 24), 
respectively (Figure 2).
Geographical spread
RSV detections peaked later with increasing latitude 
(Figure 3). There was a moderate positive correlation 
of latitude with the peak week (r = 0.56; p = 0.0360) 
and the length of the season (r = 0.57; p = 0.0329). This 
corresponds to earlier peak and shorter seasons in the 
southern parts of the EU/EEA. For start and peak of the 
season, there were moderate correlations (r = 0.52 and 
r = 0.47, respectively) to increasing longitude, although 
without statistical significance (p = 0.0563 and p = 
0.0899, respectively). 
Discussion 
In this study, we showed that in the 15 European 
countries reporting RSV surveillance data to the ECDC 
TESSy database, the average RSV season started in the 
beginning of December, peaked in early February and 
continued until early April, however, with wide varia-
tion between the countries. The data also showed a 
correlation between the earliest peak and a southerly 
latitude as well as between a longer season and a more 
northerly latitude. Furthermore, we showed that RSV 
seasonality can be captured through weekly reporting 
of RSV detections driven by diagnostic testing, using 
influenza ARI and ILI sentinel and non-sentinel surveil-
lance systems. With these results, our analysis con-
tributes to the understanding of the seasonality of RSV 
epidemics in Europe.
As previously shown in a global literature review and 
study [8], we confirmed in this study a latitudinal gradi-
ent of RSV epidemics peaking later and lasting longer 
with more northerly location of a country in the EU/EEA. 
We also showed a moderate correlation of the start and 
peak of the season with increasing longitude, although 
not statistically significant. The global study observed 
a weaker latitudinal gradient than our study, possibly 
because one third of the study sites were in the tropics 
[8]. In our study, all reporting countries were from the 
temperate climate zone in the northern hemisphere. In 
the global study, the northern hemisphere temperate 
zone covered study sites from the US to Asia, and the 
range for median RSV peak time was from December 
to February, with an epidemic duration of up to six 
months. The peak of the RSV epidemic in our study as 
well as its duration of slightly over four months is well 
in line with the range presented in the review [8] and 
in a study including seven countries from tropical and 
subtropical areas where the median length of a season 
was five months [9].
The median start week for RSV in Europe (week 49) was 
almost the same as for the US season which starts in 
week 51 (late December; range: weeks 46 to 3) [13]. 
The European and US epidemics both peak very close 
to each other: week 4 to 4.5 in our EU/EEA data and 
week 5 in the US [13]. Regions of the US experience sig-
nificant geographical variability in the start of the RSV 
season corresponding to changes in longitude and lati-
tude: in the southern states, the season starts in late 
November, in the Midwest in early January [13] and in 
Alaska between mid-October and late December [35]. 
In the US, an overall south-to-north gradient is usually 
observed for the start of the RSV epidemic [13].
The length of 13–17 weeks of the RSV season in the US 
[13] is a little shorter than what we observed (16–18 
weeks). Interestingly, the RSV epidemics last longer in 
the south of the US than in the rest of the country. We 
observed the opposite, a statistically significant posi-
tive linear correlation between latitude and season 
length in the 14 studied EU/EEA countries, i.e. the fur-
ther north the barycentre, the longer the RSV season. 
Further work is required to understand climatic and 
other factors which may be responsible for this correla-
tion with latitude.
Two-year periodicity of RSV circulation has been 
observed in national studies in Croatia [20], Finland 
[17,19], Germany [22], Norway [16] and Sweden [18]. 
We observed an earlier start to the season only for 
the 2012/13 season in eight of the 15 countries and 
for 2014/15 in three countries. Some sporadic changes 
in the season start weeks and lengths were also 
observed.
Before the introduction of an RSV vaccine, RSV sur-
veillance is required to document the baseline burden 
of disease, and the World Health Organization (WHO) 
is developing RSV surveillance [36] and following the 
RSV vaccine development with interest [29]. As no 
international RSV case definition has yet been agreed, 
the WHO has proposed candidate case definitions for 
severe and very severe RSV-associated lower respira-
tory tract infections as endpoints for RSV vaccine trials 
[29]. Further work is required to determine the optimal 
case definitions that can be applied to RSV surveil-
lance, especially surveillance of severe outcomes. We 
observed that the sentinel systems detected consid-
erably fewer RSV cases than the non-sentinel system 
detections, which is a reflection of the sentinel sys-
tem being designed to capture only a proportion of the 
population under surveillance and screening mostly 
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for influenza. The overall low numbers in sentinel sys-
tems also reflect the lower number of participating 
countries, and therefore lower overall population size, 
reporting through such a surveillance system.
Our study has a number of limitations that need to be 
considered when interpreting the results. Only 15 of 
the 30 EU/EEA Member States reported RSV detections 
and a large proportion originated from only two coun-
tries (France and UK), causing a skewed distribution. 
Therefore, results of this study should not be seen as 
representative for the entire EU/EEA, in particular for 
countries with smaller populations. No data on the 
patients’ ages were available and therefore analysis by 
age group was not possible. TESSy did not have an RSV-
specific denominator of specimens tested in this data 
collection period, nor a population denominator for 
RSV, and therefore proportions of positive specimens 
to define season start could not be calculated and 
weighting factors by population size could not be used. 
The weighting by population size could have benefited 
the study by removing the strong emphasis on the data 
from France and the United Kingdom. Using the pub-
lished method for defining the epidemic threshold [8], 
the epidemic threshold depends on the total number 
of detections per country and season and may thus be 
very low in a small country or during a low-intensity 
RSV season. We acknowledge also that only Ireland 
applied an RSV-specific case definition, and because 
the majority of detections were from non-sentinel sur-
veillance, most of the detections were collected based 
on a diagnostic need. As a large proportion of the data 
were collected as part of the national influenza surveil-
lance systems, efforts should be made in the future to 
collect specimens specifically for RSV during the influ-
enza season as focusing mainly on influenza may have 
caused a bias by detecting less RSV earlier during the 
autumn or later in spring. The surveillance systems 
and detection methods were not standardised for RSV 
detections, many systems changed during the study 
period and absolute numbers of detections may there-
fore not be comparable across countries or within coun-
tries over time. However, thresholds were calculated by 
season to detect start and peak of the RSV seasons 
even if a small number of detections were reported. As 
the EU ILI case definition that is not well-suited for RSV 
[37] was applied in some countries, the absolute num-
ber of RSV detections may have been underestimated 
in these surveillance systems. Furthermore, virological 
data were not available and it would be of interest to 
study the seasonal patterns of RSV at the level of virus 
type and genetic clade.
Despite these limitations, the present study showed 
that virological surveillance systems carried out by 
influenza reference centres or specialist and rou-
tine diagnostic laboratories that report laboratory-
confirmed RSV infections can be used to monitor 
RSV seasonality, confirming findings of the European 
Influenza Surveillance Scheme [31]. As the start of 
RSV monthly prophylaxis with palivizumab needs to 
be timed because the duration of protection is limited, 
according to the local circulation of the virus, knowing 
the seasonality at country level is of benefit for pub-
lic health. At the European level, with RSV vaccines 
expected to come to the market in the next five to 10 
years, it is crucial to establish a baseline for the num-
ber of RSV detections or for the weekly proportion of 
RSV-positive respiratory specimens to understand the 
extent of RSV circulation before implementing vacci-
nation programmes. Further work is required to deter-
mine the design of optimal surveillance systems for 
RSV to measure the impact of future RSV vaccine pro-
grammes on different age groups and on the burden of 
severe disease. Additional benefits of establishing RSV 
surveillance standards at the European level include 
the ability to compare seasonality and trends between 
countries as well as virus typing and genetic character-
isation, and to obtain standardised data on age groups 
at risk, such as newborns.
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